ContraFect Corporation
CFRX
CFRX: ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
moreShow CFRX Financials
Recent trades of CFRX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CFRX's directors and management
Government lobbying spending instances
-
$20,000 Apr 20, 2010 Issue: None
-
$20,000 Jan 20, 2010 Issue: Defense
-
$20,000 Oct 20, 2009 Issue: Defense
-
$20,000 Jul 20, 2009 Issue: Defense
-
$10,000 Apr 19, 2009 Issue: Defense
New patents grants
-
Patent Title: Biofilm prevention, disruption and treatment with bacteriophage lysin Dec. 13, 2022
-
Patent Title: Lysin polypeptides active against gram-negative bacteria Aug. 16, 2022
-
Patent Title: Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby Jun. 14, 2022
-
Patent Title: Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof Feb. 15, 2022
-
Patent Title: Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof Apr. 27, 2021
-
Patent Title: Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides Dec. 01, 2020
-
Patent Title: Bacteriophage lysin and antibiotic combinations against gram positive bacteria Oct. 27, 2020
-
Patent Title: Lysin polypeptides active against gram-negative bacteria Aug. 18, 2020
-
Patent Title: Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof May. 05, 2020
-
Patent Title: Bacteriophage lysin and antibiotic combinations against gram positive bacteria Feb. 13, 2018
-
Patent Title: Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy Aug. 01, 2017
-
Patent Title: Biofilm prevention, disruption and treatment with bacteriophage lysin Nov. 22, 2016
-
Patent Title: Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria Apr. 14, 2015
Federal grants, loans, and purchases
Followers on CFRX's company Twitter account
Number of mentions of CFRX in WallStreetBets Daily Discussion
Recent insights relating to CFRX
Recent picks made for CFRX stock on CNBC
ETFs with the largest estimated holdings in CFRX
Flights by private jets registered to CFRX